Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

Interleukin-2 (IL-2) is a T-cell proliferating factor used for cancer immunotherapy. Here, the authors develop a long-lived variant of IL-2 that, mutated in its binding domain, drives a much more potent tumour regression by depleting CD25+ CD4+regulatory T-cells via targeting them for phagocytosis.

Bibliographic Details
Main Authors: Rodrigo Vazquez-Lombardi, Claudia Loetsch, Daniela Zinkl, Jennifer Jackson, Peter Schofield, Elissa K. Deenick, Cecile King, Tri Giang Phan, Kylie E. Webster, Jonathan Sprent, Daniel Christ
Format: Article
Language:English
Published: Nature Publishing Group 2017-05-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms15373

Internet

https://doi.org/10.1038/ncomms15373

Similar Items